Title: The World of Dementia Beyond 2020
Authors: Brodaty, Henry ×
Breteler, Monique M B
Dekosky, Steven T
Dorenlot, Pascale
Fratiglioni, Laura
Hock, Christoph
Kenigsberg, Paul-Ariel
Scheltens, Philip
De Strooper, Bart #
Issue Date: 2011
Publisher: Williams & Wilkins
Series Title: Journal of the American Geriatrics Society vol:59 issue:5 pages:923-927
Article number: 10.1111/j.1532-5415.2011.03365.x
Abstract: Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments-mainly targeting the amyloid pathway, tau protein, and immunotherapy-that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia-modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.
ISSN: 0002-8614
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Department of Human Genetics - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
BrodatyH et al_World of Dementia Beyond 2020_JAGS_2011.pdfMain article Published 75KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science